Polymorphisms in methylenetetrahydrofolate reductase (MTHFR) genes result in hyperhomocysteinemia, a known risk factor for vascular damage, endothelial dysfunction, and oxidative stress found in VaD and small vessel disease patients [59]. Here, MTHFR is linked to hyperhomocysteinemia.